Otsuka Pharmaceutical Development & Commercialization, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$23Mgeneral payments (2019-2025)
$6.7Mresearch payments (2019-2025)
11,826clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Rexulti $1.2M associated (2023-2025)
- Tolvaptan $593K associated (2023-2025)
- Rejoyn $349K associated (2023-2025)
- Abilify Asimtufii $81K associated (2023-2025)
- Jynarque $63K associated (2023-2025)
- Abilify Mycite $53K associated (2023-2025)
- Abilify Maintena $27K associated (2023-2025)
- Voyxact $6,039 associated (2023-2025)
- Nuedexta $165 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Bruce Berger | Brooklyn, NY | Internal Medicine | $3,362,570.30 |
| Kevin Cox | Ojai, CA | Child & Adolescent Psychiatry | $2,877,859.03 |
| Linda Cappiello-Lindsley | Hoboken, NJ | Dermatology | $2,334,011.86 |
| Hassan Malik | Akron, OH | Internal Medicine | $1,694,125.98 |
| Maryam Saba | Springfield, VA | General Practice (Dentist) | $810,740.56 |
| Haoling Weng | Los Angeles, CA | Rheumatology | $562,398.48 |
| Wanda Castro-Borrero | Farmington, CT | Neurology (Psychiatry & Neurology) | $552,989.95 |
| Ryan Lang | Princeton, NJ | Public Health & General Preventive Medicine | $443,150.14 |
| Roshni Daver | Roxbury, MA | Internal Medicine | $322,240.00 |
| Kenechukwu Enekebe | Corpus Christi, TX | Hospitalist | $311,302.24 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.